Browse the evidence

Islet autoantibodies were present in 6.4% of overweight/obese adults with type 2 diabetes.

Practitioners should be aware that a small percentage of overweight/obese adults with type 2 diabetes may have islet autoantibodies.

Less than 25% of primary care physicians regularly refer patients for further management or track their weight-control behaviors over time.

Practitioners should note that many PCPs do not regularly refer or track weight management.

Access to new antiobesity medications is severely limited despite their potential to combat obesity.

Practitioners should be aware of the barriers to access for new antiobesity medications.

There are currently no completed randomized trials of physical activity where mortality is a prespecified primary outcome.

Current physical activity guidelines may lack robust evidence from randomized trials focused on mortality.

There was no main treatment effect of carbohydrate ingestion on blood glucose or lactate concentrations.

Carbohydrate ingestion does not significantly alter blood glucose or lactate levels during intense exercise.

Increasing levels of neurofilament light chain (NfL) are associated with worsening cognitive function and incident mild cognitive impairment or probable dementia.

Monitoring NfL levels may help in assessing cognitive decline in patients with T2D and obesity.

Increasing levels of glial fibrillary acidic protein (GFAP) are associated with worsening cognitive function and incident mild cognitive impairment or probable dementia.

Tracking GFAP levels may provide insights into cognitive health in patients with T2D and obesity.

Increasing baseline blood-based biomarker levels were not associated with any cognitive composite z score.

Baseline BBM levels may not be useful for predicting cognitive function in this population.

Existing data analytic methods for SMARTs are suitable only for superiority testing.

Current analytic methods need to be adapted for noninferiority/equivalence testing in SMARTs.

Wash-in and washout effects can threaten the validity of short-term dietary trials.

Researchers should consider the timing of interventions and outcomes in dietary trials to ensure validity.

Approximately two-thirds of patients who achieved remission relapsed within 1 year.

Practitioners should prepare for potential relapse in patients post-remission.

Type 2 Diabetes Mellitus (T2DM) is characterized by tissue insulin resistance and loss of pancreatic β cell function.

Understanding the nature of T2DM is crucial for effective management strategies.

Innovative drug delivery systems are being developed to improve the efficacy of oral antidiabetic medications.

Practitioners should consider new drug delivery methods to enhance treatment outcomes for T2DM.

There was no relationship between mitochondrial morphology or muscle respiration and 24-h energy expenditure, basal metabolic rate, or sleeping energy expenditure.

Metabolic rate may not be influenced by mitochondrial characteristics in sedentary individuals.

The term 'prediabetes' does not adequately describe the cellular changes occurring in individuals with dysglycemia.

Awareness of the limitations of the term 'prediabetes' can improve clinical understanding.

The intensive lifestyle intervention (ILI) did not result in preserved cognitive function or slower rates of cognitive decline in individuals with type 2 diabetes and overweight/obesity.

Practitioners should be cautious in expecting cognitive benefits from lifestyle interventions in this population.

There were no differences in the rate of cognitive decline by intervention arm overall.

Interventions may not impact cognitive decline rates, suggesting a need for alternative strategies.

CE/BZA treatment produced no detectable effect on insulin sensitivity, body composition, ectopic fat, fat cell size, or substrate oxidation.

CE/BZA does not improve insulin sensitivity or body composition in this population.

The encapsulated oleogel-in-oleogel system has tailorable lipid digestion compared to conventional oleogels.

This system could be used to create food products with lower calorie content and customizable fat digestion profiles.

The encapsulated oleogel-in-oleogel system maintains the nanostructure of waxes and monoglyceride crystals.

Maintaining the nanostructure could enhance the functional properties of food products using this system.

The digestibility of the encapsulated oleogel-in-oleogel system can be modulated by varying the ratio of its components.

This flexibility allows for the design of food products tailored to specific dietary needs.

Highly unsaturated fatty acids (HUFA) have n-3 and n-6 motifs with documented differences in intensity of destabilizing positive feedback loops amplifying pathophysiology.

Understanding the role of HUFA can inform dietary recommendations for cardiovascular health.

Non-esterified fatty acids (NEFA) increase negative charge of LDL and decrease its processing by 'normal' receptors while increasing processing by 'scavenger' receptors.

This knowledge can guide interventions targeting LDL metabolism in clinical nutrition.

GIPR activation influences energy balance and insulin sensitivity through mechanisms involving metabolic and thermogenic genes.

Understanding the molecular mechanisms of GIPR could inform strategies for improving insulin sensitivity.